Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Ranbaxy losses pile up as it awaits the healing powers of Sun

09.05.2014 / Fierce Pharma

With its $3.2 billion buyout of Ranbaxy Laboratories, Sun Pharmaceutical is not only buying a business in need of serious manufacturing improvements, but one that is bleeding money as FDA bans keep it from launching exclusive generics for blockbusters like Novartis' Diovan and AstraZeneca's Nexium.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: